Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
Hs 578T Ceritinib
10.0
ALK
RTK
 -0.4356 0.67418
Hs 578T Neratinib
0.00031623
EGFR/HER2
RTK
 1.0519 0.00196
Hs 578T Neratinib
0.001
EGFR/HER2
RTK
 1.0056 0.00191
Hs 578T Neratinib
0.0031623
EGFR/HER2
RTK
 1.0284 0.00123
Hs 578T Neratinib
0.01
EGFR/HER2
RTK
 0.9849 0.00721
Hs 578T Neratinib
0.031623
EGFR/HER2
RTK
 1.0125 0.00436
Hs 578T Neratinib
0.1
EGFR/HER2
RTK
 0.8904 0.00379
Hs 578T Neratinib
0.31623
EGFR/HER2
RTK
 0.6171 0.03083
Hs 578T Neratinib
1.0
EGFR/HER2
RTK
 0.3961 0.05354
Hs 578T Neratinib
3.1623
EGFR/HER2
RTK
 -0.1608 0.49406
Hs 578T Tivantinib
0.001
MET
RTK
 0.9977 -0.00266
Hs 578T Tivantinib
0.0031623
MET
RTK
 1.0093 -0.00309
Hs 578T Tivantinib
0.01
MET
RTK
 0.9961 0.00485
Hs 578T Tivantinib
0.031623
MET
RTK
 1.0860 0.00272
Hs 578T Tivantinib
0.1
MET
RTK
 0.9354 0.02797
Hs 578T Tivantinib
0.31623
MET
RTK
 0.5368 0.14448
Hs 578T Tivantinib
1.0
MET
RTK
 -0.1162 0.44578
Hs 578T Tivantinib
3.1623
MET
RTK
 -0.2792 0.56579
Hs 578T Tivantinib
10.0
MET
RTK
 -0.3204 0.67768
Hs 578T Cediranib
0.001
VEGFR/cKIT
RTK
 1.0163 -0.00048
Hs 578T Cediranib
0.0031623
VEGFR/cKIT
RTK
 0.9935 0.00404
Hs 578T Cediranib
0.01
VEGFR/cKIT
RTK
 0.9644 0.00188
Hs 578T Cediranib
0.031623
VEGFR/cKIT
RTK
 0.8397 0.01896
Hs 578T Cediranib
0.1
VEGFR/cKIT
RTK
 0.7275 0.02636
Hs 578T Cediranib
0.31623
VEGFR/cKIT
RTK
 0.5611 0.05612